3.145
2.02%
-0.065
Lantern Pharma Inc stock is traded at $3.145, with a volume of 38,603.
It is down -2.02% in the last 24 hours and up +6.97% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.21
Open:
$3.17
24h Volume:
38,603
Relative Volume:
0.72
Market Cap:
$33.92M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-2.3801
EPS:
-1.3214
Net Cash Flow:
$-17.24M
1W Performance:
-8.71%
1M Performance:
+6.97%
6M Performance:
-29.17%
1Y Performance:
-18.94%
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.145 | 33.92M | 0 | -19.09M | -17.24M | -1.78 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance
15 AI News Updates That Broke The Internet - Insider Monkey
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com
LP-184 gains FDA fast track for triple negative breast cancer - Investing.com
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune
Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace
Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com
Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate, Expands to Japan Trial | LTRN Stock News - StockTitan
32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.
III: TechBio News Day 👾 - substack.com
LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance
Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace
Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Simply Wall St
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board - Yahoo Finance
Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire
Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire
FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace
FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com
After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph
11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex
Lantern Pharma secures three new FDA rare disease tags - Investing.com
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace
Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch
Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
Fletcher Aaron G.L. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
Fletcher Aaron G.L. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
Fletcher Aaron G.L. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
Kreis Leslie W. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
Kreis Leslie W. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
Kreis Leslie W. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
Fletcher Aaron G.L. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
Kreis Leslie W. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):